>
Avivagen Inc logo

VIV - Avivagen Inc Share Price

C$0.48 -0.0  -2.0%

Last Trade - 16/04/21

Sector
Consumer Defensives
Size
Micro Cap
Market Cap £11.5m
Enterprise Value £15.1m
Revenue £689k
Position in Universe 1631st / 2713
Bullish
Bearish
Unlock VIV Revenue
Momentum
Relative Strength (%)
1m -28.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Oct 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.16 0.011 0.26 1.07 0.98 1.18 3.86 12.2 +48.3%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 January 2021, AvivagenInc revenues increased 6% to C$262K. Net loss decreased 5%to C$1.3M. Revenues reflect Thailand (Country) segmentincrease of 93% to C$16K, Philippines segment remainingflat at C$225K. Lower net loss reflects Professional feesand other decrease of 22% to C$535K (expense), Share-basedpayments decrease of 19% to C$47K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VIV Revenue Unlock VIV Revenue

Net Income

VIV Net Income Unlock VIV Revenue

Normalised EPS

VIV Normalised EPS Unlock VIV Revenue

PE Ratio Range

VIV PE Ratio Range Unlock VIV Revenue

Dividend Yield Range

VIV Dividend Yield Range Unlock VIV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VIV EPS Forecasts Unlock VIV Revenue
Profile Summary

Avivagen Inc is a Canada-based life sciences company. It develops products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its segments include products based on fully-oxidized beta-carotene (OxC-beta) technology and chemistry product sales. Its OxC-beta technology is in trials as a non-antibiotic feed additive. Its products include OxC-beta Livestock, Vivamune Health Chews and Oximunol Chewable Tablets. Its Vivamune Health Chews are supplements that are suitable for pets in all life stages and can be given to dogs and cats as young as over five weeks of age. The Oximunol Chewable Tablets are available in bottles through veterinarians across the United States. The OxC-beta Livestock is available for sale in Taiwan, Thailand and the Philippines. Its customers include government agencies, global health organizations, livestock producers and end market food companies.

Directors
Last Annual October 31st, 2020
Last Interim January 31st, 2021
Incorporated November 1, 2017
Public Since March 2, 2001
No. of Shareholders: n/a
No. of Employees: n/a
Sector Consumer Defensives
Industry Food & Tobacco
Index
Exchange TSX Venture Exchange
Shares in Issue 41,487,979
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VIV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VIV
Upcoming Events for VIV
Frequently Asked Questions for Avivagen Inc
What is the Avivagen Inc share price?

As of 16/04/21, shares in Avivagen Inc are trading at C$0.48, giving the company a market capitalisation of £11.5m. This share price information is delayed by 15 minutes.

How has the Avivagen Inc share price performed this year?

Shares in Avivagen Inc are currently trading at C$0.48 and the price has moved by -22.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Avivagen Inc price has moved by -42.46% over the past year.

What are the analyst and broker recommendations for Avivagen Inc?

Of the analysts with advisory recommendations for Avivagen Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Avivagen Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Avivagen Inc next release its financial results?

Avivagen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-01-31
What is the Avivagen Inc dividend yield?

Avivagen Inc does not currently pay a dividend.

Does Avivagen Inc pay a dividend?

Avivagen Inc does not currently pay a dividend.

When does Avivagen Inc next pay dividends?

Avivagen Inc does not currently pay a dividend.

How do I buy Avivagen Inc shares?

To buy shares in Avivagen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Avivagen Inc?

Shares in Avivagen Inc are currently trading at C$0.48, giving the company a market capitalisation of £11.5m.

Where are Avivagen Inc shares listed? Where are Avivagen Inc shares listed?

Here are the trading details for Avivagen Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: VIV
What kind of share is Avivagen Inc?

Based on an overall assessment of its quality, value and momentum, Avivagen Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Avivagen Inc share price forecast 2021?

Shares in Avivagen Inc are currently priced at C$0.48. At that level they are trading at 0.317% discount to the analyst consensus target price of 0.00.

Analysts covering Avivagen Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.09 for the next financial year.

How can I tell whether the Avivagen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avivagen Inc. Over the past six months, the relative strength of its shares against the market has been -9.15%. At the current price of C$0.48, shares in Avivagen Inc are trading at -7.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Avivagen Inc PE Ratio?

We were not able to find PE ratio data for Avivagen Inc.

Who are the key directors of Avivagen Inc?

Avivagen Inc's management team is headed by:

Graham Burton - OTH
David Hankinson - NVC
Chris Boland - CFO
G.F. Anthony - PRE
Paul Mesburis - IND
Aubrey Dan - DRC
Jeffrey Kraws - NEC
Who are the major shareholders of Avivagen Inc?

Here are the top five shareholders of Avivagen Inc based on the size of their shareholding:

Anthony (Carole) Individual Investor
Percentage owned: 1.2% (500k shares)
Dan (Aubrey) Individual Investor
Percentage owned: 1.2% (500k shares)
Anthony (G F Kym) Individual Investor
Percentage owned: 0.64% (267k shares)
Burton (Graham) Individual Investor
Percentage owned: 0.59% (246k shares)
Kraws Jeffrey J Individual Investor
Percentage owned: 0.12% (50.0k shares)
Similar to VIV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.